Eddingpharm Inc:製薬・医療:M&Aディール及び事業提携情報

◆英語タイトル:Eddingpharm Inc - Pharmaceuticals & Healthcare - Deals and Alliances Profile
◆商品コード:DATA904C10599
◆発行会社(調査会社):GlobalData
◆発行日:2018年11月
◆ページ数:34
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆対象地域:中国
◆産業分野:製薬・医療
◆販売価格オプション(消費税別)
Single User(1名様閲覧用)USD250 ⇒換算¥37,000見積依頼/購入/質問フォーム
Site License(同一事業所内共有可)USD500 ⇒換算¥74,000見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD750 ⇒換算¥111,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
GlobalData社の概要はこちらでご確認いただけます。



【レポートの概要】

Summary
Eddingpharm Inc (Eddingpharm) is a pharmaceutical company that manufactures and distributes medicines. The company develops products in therapeutic areas such as clinical nutrition, antibiotics, respiratory system, nephrology and cardiovascular. It offers antibiotics including vancocin, ceclor, fortum, zinacef inj and zinacef tab. Eddingpharm’s nutrition products comprise lipoplus, lipofundin, nutriflex lipid peri and aminoplasmal hepa. The company provides clinical trial management and product registration services. It partners with multinational pharmaceutical and biotech companies. The company operates through its branch offices and logistics center in Beijing, Guangzhou, Chengdu, Macau and Taizhou, China. Eddingpharm is headquartered in Shanghai, China.

Eddingpharm Inc – Pharmaceuticals & Healthcare – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.

Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

【レポートの目次】

Table of Contents
Table of Contents 3
List of Tables 4
List of Figures 4
Eddingpharm Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
Eddingpharm Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 6
Eddingpharm Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
Eddingpharm Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 8
Eddingpharm Inc, Medical Devices Deals, 2012 to YTD 2018 9
Eddingpharm Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 10
Eddingpharm Inc, Pharmaceuticals & Healthcare, Deal Details 12
Asset Purchase 12
Eddingpharm Acquires Global Rights Oncology Assets From ACT Biotech For US$95 Million 12
Venture Financing 14
EOC Pharma Raises USD32 Million in Series B Venture Financing 14
Partnerships 15
OncBioMune Pharma to Enter into Agreement with EOC Pharma 15
Eddingpharm Enters into Agreement with Eli Lilly 16
Faes Farma to Form Joint Venture with Eddingpharm 17
Amarin Enters into Development Agreement with Eddingpharm 18
Cardiome Pharma Enters into Agreement with Eddingpharm to Develop and Commercialize Brinavess 19
ALK-Abello Enters Into Co-Marketing Agreement With Eddingpharm 20
Immutep Enters into Development Agreement with Eddingpharm for ImmuFact IMP321 21
Eddingpharm Forms Joint Venture With Chiesi Farmaceutici 22
Eddingpharm Enters Into Distribution Agreement With GlaxoSmithKline For Tykerb 23
Eddingpharm Enters Distribution Agreement With GlaxoSmithKline For Relafen 24
Licensing Agreements 25
Eddingpharm Enters into Licensing Agreement with Suda 25
Eddingpharm Enters into Licensing Agreement with Correvio International 26
Ablynx Enters into Licensing Agreement with Eddingpharm for Anti-TNFa Nanobody 27
Ablynx Enters Into Licensing Agreement With Eddingpharm 28
Syndax Pharma Enters Into Licensing Agreement With Eddingpharm For Entinostat 30
Eddingpharm Inc – Key Competitors 31
Eddingpharm Inc – Key Employees 32
Eddingpharm Inc – Locations And Subsidiaries 33
Head Office 33
Other Locations & Subsidiaries 33
Appendix 34
Methodology 34
About GlobalData 34
Contact Us 34
Disclaimer 34

List of Tables
Eddingpharm Inc, Pharmaceuticals & Healthcare, Key Facts 2
Eddingpharm Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
Eddingpharm Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 6
Eddingpharm Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
Eddingpharm Inc, Deals By Therapy Area, 2012 to YTD 2018 8
Eddingpharm Inc, Medical Devices Deals, 2012 to YTD 2018 9
Eddingpharm Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 10
Eddingpharm Acquires Global Rights Oncology Assets From ACT Biotech For US$95 Million 12
EOC Pharma Raises USD32 Million in Series B Venture Financing 14
OncBioMune Pharma to Enter into Agreement with EOC Pharma 15
Eddingpharm Enters into Agreement with Eli Lilly 16
Faes Farma to Form Joint Venture with Eddingpharm 17
Amarin Enters into Development Agreement with Eddingpharm 18
Cardiome Pharma Enters into Agreement with Eddingpharm to Develop and Commercialize Brinavess 19
ALK-Abello Enters Into Co-Marketing Agreement With Eddingpharm 20
Immutep Enters into Development Agreement with Eddingpharm for ImmuFact IMP321 21
Eddingpharm Forms Joint Venture With Chiesi Farmaceutici 22
Eddingpharm Enters Into Distribution Agreement With GlaxoSmithKline For Tykerb 23
Eddingpharm Enters Distribution Agreement With GlaxoSmithKline For Relafen 24
Eddingpharm Enters into Licensing Agreement with Suda 25
Eddingpharm Enters into Licensing Agreement with Correvio International 26
Ablynx Enters into Licensing Agreement with Eddingpharm for Anti-TNFa Nanobody 27
Ablynx Enters Into Licensing Agreement With Eddingpharm 28
Syndax Pharma Enters Into Licensing Agreement With Eddingpharm For Entinostat 30
Eddingpharm Inc, Key Competitors 31
Eddingpharm Inc, Key Employees 32
Eddingpharm Inc, Other Locations 33
Eddingpharm Inc, Subsidiaries 33

List of Figures
Eddingpharm Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2
Eddingpharm Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2
Eddingpharm Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2
Eddingpharm Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2
Eddingpharm Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
Eddingpharm Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 6
Eddingpharm Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
Eddingpharm Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 8
Eddingpharm Inc, Medical Devices Deals, 2012 to YTD 2018 9

★海外企業調査レポート[Eddingpharm Inc:製薬・医療:M&Aディール及び事業提携情報]についてメールでお問い合わせはこちら

■おすすめ企業レポート■
  • Shikoku Electric Power Co Inc (9507):企業の財務・戦略的SWOT分析
    Shikoku Electric Power Co Inc (9507) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and …
  • Vertex Pharmaceuticals Inc (VRTX):企業の財務・戦略的SWOT分析
    Vertex Pharmaceuticals Inc (VRTX) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and we …
  • Oil Refineries Ltd (ORL):企業の財務・戦略的SWOT分析
    Oil Refineries Ltd (ORL) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses …
  • Pt Bank Central Asia Tbk:企業の戦略・SWOT・財務分析
    Pt Bank Central Asia Tbk - Strategy, SWOT and Corporate Finance Report Summary Pt Bank Central Asia Tbk - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service o …
  • Arcturus Therapeutics Ltd (ARCT):製薬・医療:M&Aディール及び事業提携情報
    Summary Arcturus Therapeutics Ltd (Arcturus), formerly Alcobra Ltd is a pharmaceutical company that develops a portfolio of nucleic acid therapeutics for treatment of diseases with unmet medical needs. It discovers and develops RNA medicines and design and utilize lipid-mediated drug delivery system …
  • Dongbu Insurance Co., Ltd.:企業の戦略・SWOT・財務情報
    Dongbu Insurance Co., Ltd. - Strategy, SWOT and Corporate Finance Report Summary Dongbu Insurance Co., Ltd. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and servi …
  • Goodfellow Inc (GDL):企業の財務・戦略的SWOT分析
    Goodfellow Inc (GDL) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and …
  • Protagen Protein Services GmbH:製薬・医療:M&Aディール及び事業提携情報
    Summary Protagen Protein Services GmbH (PPS), a subsidiary of Zukunftsfonds Heilbronn GmbH & Co KG is a contract research organization that offers protein analytics. The organization offers services such as services for biopharmaceuticals, protein characterization, biosimilars services, and analytic …
  • Xcel Energy Inc:発電所・企業SWOT分析
    Xcel Energy Inc - Power Plants and SWOT Analysis, 2017 Update Summary The report contains a detailed description of the power generation company’s business operations, history, corporate strategy, and business structure. This report contains a detailed SWOT analysis, information on key employees (ex …
  • NCC Group plc:企業の戦略・SWOT・財務情報
    NCC Group plc - Strategy, SWOT and Corporate Finance Report Summary NCC Group plc - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corporate …
  • Corby Spirit and Wine Limited:企業の戦略・SWOT・財務分析
    Corby Spirit and Wine Limited - Strategy, SWOT and Corporate Finance Report Summary Corby Spirit and Wine Limited - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and …
  • PT Dian Swastatika Sentosa Tbk (DSSA):企業の財務・戦略的SWOT分析
    PT Dian Swastatika Sentosa Tbk (DSSA) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths an …
  • Norgine BV:医療機器:M&Aディール及び事業提携情報
    Summary Norgine BV (Norgine) is a pharmaceutical company that offers medicinal products. The company develops drugs in the therapeutic areas of gastroenterology, incontinence, hepatology and critical and supportive care and pain management, among others. It offers the treatment of diseases related t …
  • EpiVax Inc:製薬・医療:M&Aディール及び事業提携情報
    Summary EpiVax Inc (EpiVax) develops analytical capabilities in the field of computational immunology. Its product pipeline includes Tregitopes; deimmunization projects including deimmunized botox and deimmunized FVIII; and biodefense vaccines. Tregitopes are linear sequences of amino acids which ac …
  • Vital Therapies Inc (VTL):医療機器:M&Aディール及び事業提携情報
    Summary Vital Therapies Inc (Vital Therapies) is a biotechnology company that discovers, develops and commercialize cell-based therapies. The company’s product candidate includes ELAD system, a human-cell-based bio artificial liver treatment designed to allow the patient's own liver to regenerate or …
  • Sc Arcada Con Srl:企業の戦略的SWOT分析
    Sc Arcada Con Srl - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and serv …
  • China Overseas Land & Investment Limited:企業の戦略・SWOT・財務情報
    China Overseas Land & Investment Limited - Strategy, SWOT and Corporate Finance Report Summary China Overseas Land & Investment Limited - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT …
  • Cellmid Ltd (CDY)-医療機器分野:企業M&A・提携分析
    Summary Cellmid Ltd (Cellmid), formerly Medical Therapies Ltd is a developer of therapies and diagnostic tests. The company holds comprehensive portfolio of intellectual property relating to the novel targets midkine and FGF5. It offers products such as midkine ELISA kit, advangen international hair …
  • Hals-Development:企業の戦略・SWOT・財務情報
    Hals-Development - Strategy, SWOT and Corporate Finance Report Summary Hals-Development - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and cor …
  • PT. SOHO Industri Pharmasi:製薬・医療:M&Aディール及び事業提携情報
    Summary PT. SOHO Industri Pharmasi (PT SOHO), a subsidiary of SOHO Global Health, is a pharmaceutical company that offers ethical, consumer health, herbal medicine and natural products. The company’s products include analgesic, anti-inflammatory, antipyretic, antibiotics, antifungal, antihistamine a …

◆H&Iグローバルリサーチ株式会社のお客様(例)◆